(Q34683219)

3 August 2017

1 reference

title

Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products (English)

1 reference

3 August 2017

Sudhish Chandra

1

1 reference

3 August 2017

A Groener

series ordinal

2

1 reference

3 August 2017

F Feldman

series ordinal

3

1 reference

3 August 2017

publication date

1 March 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

105

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

391-400

1 reference

Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Treatment of inherited coagulation disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Reducing the infectivity of blood components--what we have learned

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Congenital bleeding disorders. Rational treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Antithrombin: its physiological importance and role in DIC.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Serine proteinase inhibitor therapy in alpha(1)-antitrypsin inhibitor deficiency and cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

αl-Antitrypsin Deficiency: An Overview

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Hemostatic efficacy of fibrin sealant (human) on expanded poly-tetrafluoroethylene carotid patch angioplasty: a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Viral safety of clotting factor concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Regulatory affairs and biotechnology in Europe: III. Introduction into good regulatory practice--validation of virus removal and inactivation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Real time quantitative PCR as a method to evaluate simian virus 40 removal during pharmaceutical protein purification

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Safety of coagulation factor concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Evaluation of a new PCR assay with competitive internal control sequence for blood donor screening

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Genomic screening for blood-borne viruses in transfusion settings

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. I. THE CHARACTERIZATION OF THE PROTEIN FRACTIONS OF HUMAN PLASMA.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

The removal of model viruses, poliovirus type 1 and canine parvovirus, during the purification of human albumin using ion-exchange chromatographic procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Removal and inactivation of enveloped and non-enveloped viruses during the purification of a high-purity factor IX by metal chelate affinity chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Improved safety from plasma derivatives: purification and viral elimination characteristics of mononine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Inactivation of viruses during ultraviolet light treatment of human intravenous immunoglobulin and albumin.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Virus reduction in the preparation of intravenous immune globulin: in vitro experiments

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Inactivation of hepatitis A virus by heat treatment in aqueous solution

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Biochemical and physical properties of a solvent-detergent-treated fibrin glue.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900044-0

7 January 2021

10.1016/S0049-3848(02)00044-0

Identifiers

DOI

1 reference

release_6ztnh6c4mjebtj7y5za3lmssym

3 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6ztnh6c4mjebtj7y5za3lmssym

24 November 2022

mapped directly with Wikidata item

1 reference